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ABSTRACT
Objective: To summarize themethodological approaches used in published
decision-analytic models evaluating interventions for acute stroke treat-
ment, to highlight key components of decision-analytic models of stroke
treatment, and to discuss challenges for developing stroke decision models.
Methods: A review of the published literature was performed using
Medline, to identify studies involving mathematical decision models to
evaluate interventions for acute stroke treatment. Articles were analyzed
to determine key components of a stroke model and to note areas in which
data are lacking.
Results: We identiﬁed 13 published models of acute stroke treatment.
These models typically possessed a short-term treatment module and a
long-term post-treatment module. The following aspects of economic
modeling were found to be relevant for developing a stroke model:
modeling approach and health state; health state transition probabilities;
estimation of short-term, long-term, and indirect costs; health state utili-
ties; poststroke mortality; time horizon; model validation; and estimation
of parameter uncertainty.
Conclusions: Data gaps have limited the development of economic models
in stroke to date. In order to more accurately assess the long-term incre-
mental impact of a new treatment of stroke, future research is needed to
address these data gaps. We recommend that the complexity of models for
examining the cost-effectiveness of an acute stroke treatment be kept to a
minimum such that it can incorporate the currently available data without
making a large number of assumptions around the data.
Keywords: cost-effectiveness analysis, decision analysis, stroke outcomes,
systematic review.
Introduction
Stroke is a major health concern and is the third leading cause of
death behind heart disease and cancer in the United States (US)
[1]. It is also the leading cause of serious, long-term disability in
the US. The length of time to recover from a stroke depends on
its severity. Approximately 50% to 70% of stroke survivors
regain functional independence, but 15% to 30% of survivors
are permanently disabled, and 20% require institutional care at
3 months after onset [2].
Economic models can serve an important purpose for
decision-making in the treatment of acute stroke. With limited
health-care resources, it is important to allocate healthcare
resources to interventions that are most cost-effective (i.e., have
the greatest beneﬁt per cost). In stroke, beneﬁts of acute treat-
ment extend far beyond the initial hospitalization and acute care.
In fact, the lasting effect on functional outcome may result in
substantial long-term costs. Since most clinical trials do not
measure functional outcome beyond 3 to 6 months following the
stroke, they fail to capture the economic/clinical impact in the
long term. As a result, decision-analytic modeling is an important
tool for examining the cost-effectiveness of acute stroke treat-
ments in the absence of this complete and perfect information.
These exercises enable decision-makers to examine the effects of
a new therapy and its potential impact on costs and quality of life
in a cost-efﬁcient manner.
To date, several economic models have been developed to
estimate the cost-effectiveness of acute stroke treatments. These
models have focused primarily on the inpatient and poststroke
rehabilitation costs, as well as the utility associated with varying
degrees of poststroke disability and mortality. This article
reviews various published cost-effectiveness analyses for treat-
ment of stroke including use of recombinant tissue plasminogen
activator (tPA) for ischemic stroke and recombinant activated
factor VII (rFVIIa) for treatment of hemorrhagic stroke, with a
speciﬁc emphasis on decision-analytic approaches. First, we
review the design and setup, analytic approach, inputs and
outputs, and validation approach for each of these models. We
then discuss the challenges of developing a decision-analytic
model in order to properly assess the cost-effectiveness of acute
stroke treatments. Speciﬁcally, we highlight key components of
the decision-analytic models and discuss challenges of obtaining
data to populate these models.
Methods
A Medline search (1990 through 2007) was performed to iden-
tify decision-analytic models developed to assess the cost-
effectiveness of acute stroke treatments. The initial search terms
included “economic model,” “cost-effectiveness,” “decision-
analytic model,” “stroke,” “thrombolysis,” “tissue plasminogen
activator,” and “recombinant factor VIIa.” In addition, we
examined the reference lists of identiﬁed studies. Articles were
limited to those in the English language only, and articles with no
abstracts were excluded.
Inclusion criteria for the review were that studies must be an
evaluation of a treatment strategy or therapeutic intervention
using decision-analytic modeling or some other form of mathe-
matical modeling. This included Markov models, decision-tree
models, and models based on mathematical equations.
Data were reviewed independently by two of this study’s
authors (SRE and MW). Data were then summarized in evidence
tables. The following parameters were included in the evidence
tables for each study:
• author and year;
• country of analysis;
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• stroke type and comparators;
• type of analysis;
• data sources;
• main results;
• conclusions;
• time horizon;
• modeling approach;
• outcomes measured;
• consideration of parameter uncertainty; and
• model validation.
The evidence tables were reviewed separately by the authors,
conﬁrmed, and ﬁnalized. The tables were used to assist in the
discussion of modeling approaches and gaps in available data for
modeling treatments of acute stroke.
Results
Figure 1 illustrates the results of the literature search. The initial
literature search identiﬁed 753 articles. Abstracts of each article
were reviewed to exclude articles on topics such as preventive
interventions. From this review, we identiﬁed 10 articles that
relate to modeling studies of treatment of an acute stroke event.
References within in each of these article were reviewed, which
identiﬁed 5 more articles for a total of 15 articles. One of the 15
articles was excluded as it claimed to analyze acute stroke treat-
ment; however, it did not report results on that treatment [3]. A
second article was excluded because it focused on modeling
various computed tomography scanning strategies throughout
treatment rather than treatment of acute stroke events [4]. The
articles include several models of thrombolytic therapy with tPA
for ischemic stroke, one model of treatment for intracerebral
hemorrhage (ICH), and models designed to be used for estimat-
ing cost-effectiveness of acute stroke treatment. A summary
of the 13 cost-effectiveness models assessing treatment of
acute stroke events included in the review are presented in
Tables 1 and 2.
Chambers et al. 2002
Chambers et al. [5] developed a model (Stroke Outcomes Model)
of ischemic stroke treatment in France, Germany, the United
Kingdom (UK) and the US that examines the impact on costs, life
years, and QALYs. The model was designed to compare different
scenarios including acute stroke treatment (tPA vs. no early acute
therapy) as well as prevention treatments (aspirin vs. aspirin-
dipyridamole) for recurrent stroke over a time horizon of 25
years (assumed to be the lifetime of a patient). The model was
designed to be a cohort analysis of 1000 patients and was devel-
oped in TreeAge software (TreeAge, Williamstown, MA) with
parameters calculated and model results presented in Microsoft
Excel (Excel) (Microsoft, Redmond, WA). The model contains
two modules: an acute care module and a long-term care and
prevention of recurrence module. The acute module is a decision
tree model with a 90-day time horizon and considers morbidity,
mortality, and risk of symptomatic ICH. For survivors, the
90-day acute module becomes the ﬁrst cycle of the long-term
module. The long-term module used a Markov approach with
3-month cycles to estimate mortality, disability, and risk of recur-
rent stroke.
The model structure within this study is thoroughly
described. The strength of the model is its comprehensiveness in
that it addresses the full continuum of care, from treatment of the
acute stroke event to prevention of recurrent stroke, to postre-
current stroke functional outcome, and to death. The authors
have nicely illustrated the generalizability of the model by pre-
senting adaptations of the model for several countries such as
France, Germany, and the US. In addition, although not detailed
in the article, the authors note adaptations have been made for
Spain and Canada. As noted by the authors, the model is limited
by the availability of cost data, particularly in the long term and
in terms of disability. Presentation of more detail around sensi-
tivity analyses would have further strengthened the results of the
analysis.
Fagan et al. 1998
Fagan et al. [6] developed a cost-effectiveness and cost-utility
model of ischemic stroke treatment in the US for a 1000-patient
cohort. The model was programmed using CyrstalBall to
perform probabilistic sensitivity analysis (denoted as multiway
sensitivity analysis in the article). It is assumed that the base
model was programmed in a standard spreadsheet package,
although details are not speciﬁed in paper. The model compared
treatment with tPA and placebo over a 30-year time horizon. The
model used a decision tree to estimate acute stroke treatment. A
Markov approach was used to estimate long-term outcomes
based on discharge location and risk of recurrent stroke. Patients
in the model experienced a risk of symptomatic ICH. After initial
Abstracts identified in literature 
search
(N=753)
Articles meeting criteria for review
(N=10)
Abstracts excluded
(N=743)
Articles meeting criteria from 
review of references
(N=5)
Articles included in review
(N=13)
Articles excluded
(N=2)
1 = No acute stroke results
1 = Not treatment-related
Figure 1 Results of literature search.
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hospitalization, patients were discharged either to a nursing
home, to rehabilitation, or to their own homes. Following dis-
charge, these patients experienced a risk of recurrent stroke and
increased mortality risk over that of the general population.
This carefully performed study is important, as it was perhaps
the ﬁrst to examine the cost-effectiveness of tPA. The model
structure outlined within this study has been the basis from
which further tPA studies have been created. As a result, it has
been found to be useful in adapting for analyses in other coun-
tries. A weakness of the study is that limited data are presented
around certain parameter values such as actual rehabilitation,
nursing home cost values, and recurrent stroke risk. It is there-
fore difﬁcult to replicate the results of this analysis. In running
probabilistic sensitivity analysis, the binomial distribution was
assumed when varying functional outcome and death at 10 days,
3 months, 6 months, and 1 year; and uniform distributions were
assumed for most other parameter values. These are not typical
distributions assumed when running probabilistic analyses.
However, lack of knowledge of the actual distributions around
speciﬁc data is typical within most models.
Samsa et al. 2002
We debated whether to include this analysis within our review of
the use of decision-analytic models to assess the cost-effectiveness
of treatments for acute stroke events, as it could be debated that
the setup of this analysis is similar to that of a within-trial
analysis with the application of various derived costs and out-
comes for each patient. However, because much of the data
critical to performing the analysis over a long-term time horizon
were obtained from a simulation model, we chose to consider
this study. Samsa et al. [7] performed a cost-utility analysis to
compare the use of ancrod to standard care for the treatment of
ischemic stroke in a patient cohort recruited for the Stroke Treat-
ment with Ancrod Trial (STAT). The analysis was set up using the
approach outlined in their previous analyses [8,9] in which short-
term costs and outcomes were estimated from a 90-day clinical
trial. Long-term outcomes for each patient were estimated using
the Stroke Prevention Policy Model (SPPM), a semi-Markov
simulation model. A potential hurdle occurred within the analy-
sis in that the SPPM was set up to report long-term outcomes by
modiﬁed Rankin Scale (mRS), but the STAT reported a 90-day
functional outcome based on the Barthel Index (BI). Data from
the Kansas City Stroke Study were used to map mRS to BI
categories. Authors do not detail what software in which this
analysis was programmed. Because this analysis involved patient-
level data, it is most likely that it was programmed in a statistical
analysis software package such as SAS or a spreadsheet package
in which outputs from the SPPM would have been applied as
additional patient variables.
This carefully performed study is important as it demon-
strates a real-life analysis of an acute stroke treatment using the
comprehensively developed SPPM. As a result, it builds on exist-
ing modeling approaches. As such, the methodological approach
used within this study could be applied in other countries.
However, the adaptation of this approach for use in another
country would be difﬁcult as this analysis relies on the
US-developed SPPM and its data. A limitation of this study as
noted by the authors is that the long-term outcomes obtained
from the SPPM and applied to the immediate analysis were based
on clinical practice patterns in 1990.
Moodie et al. 2004
Moodie et al. [10] performed a cost-effectiveness analysis of
aspirin as an antiplatelet agent and tPA treatment compared to
current practice in a cohort of 30,895 ﬁrst-ever stroke patients.
The model used was the Model of Resource Utilization, Costs,
and Outcomes for Stroke (MORUCOS) model [11] developed
to perform cost and burden analyses in an Australian setting.
As outlined in the summary of the Mihalopoulos et al. model
approach [11], the model was programmed using Microsoft
Excel, with interaction between TreeAge and @Risk.
This study builds upon the MORUCOS model presented by
Mihalopoulos et al. [11] and presents more description around
input parameters assumed for and results of treating patients
with aspirin therapy and tPA as compared to more current prac-
tice than that presented in Mihalopoulos et al. [11]. The authors
note within the study that this model could be adapted to
perform analyses within other countries. They speciﬁcally state
that it is “readily recalibrated with alternative data inputs for
other geographical regions.” However, our assessment is that this
adaptation would be difﬁcult given the limited information pre-
sented around the model construct. The authors would need to
be contacted for such adaptations. This study could have been
strengthened by presenting results in Australian dollars rather
than US dollars as the resource use and perspective of the model
is that of Australia. The article is further limited in its presenta-
tion of sensitivity analysis results and details around speciﬁc
input parameters tested, and in its assumptions around ranges
and distributions for parameters varied in probabilistic sensitiv-
ity analysis.
Sandercock et al. 2004
Sandercock et al. [12] developed a cost-utility model of the use of
tPA for the treatment of ischemic stroke in a UK setting. The
model compared standard care to tPA plus standard care over a
1-year period and the lifetime of a patient following stroke onset.
Costs and outcomes in the ﬁrst year following the stroke event
were estimated for a cohort of 100 patients using a decision-tree
model. Outcomes after the ﬁrst year were estimated using a
Markov approach. The model was programmed using the
TreeAge software. The Markov design used age-speciﬁc mortal-
ity, risk of recurrent stroke, and stroke-speciﬁc mortality to esti-
mate the transition probabilities among three health states: dead,
alive and dependent, and alive and independent.
In this carefully performed study, a complete analysis of the
use of tPA for the treatment of acute stroke within the UK is
presented. The analysis relies on data from the UK setting.
Authors are careful to consider differences in costs and outcomes
that may occur across different centers in the UK. Another
strength of the analysis is that the authors considered the efﬁcacy
of tPA based on a systematic review of tPA clinical trials rather
than basing the efﬁcacy on results from one trial. Thus, the
analysis accounts for greater variability of efﬁcacy that may be
seen across different patient populations. The model developed
for this analysis is similar to other models. As such, country
adaptations could be possible. However, limited information
around probability distributions used for running the probabi-
listic sensitivity analysis (referred to as multiway sensitivity
analysis using Monte Carlo simulation within the article) are
presented, making replication of these results difﬁcult.
Mar et al. 2004
Mar et al. [13] developed a cost-utility model comparing acute
ischemic stroke treatment with tPA versus standard care. The
model was constructed as a Markov model in which a cohort of
patients transitioned through the model with 1-year cycle times
over a lifetime time horizon. Health states, programmed in
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Microsoft Excel, included stroke, autonomous (BI  95), dis-
abled (BI < 95), recurrent stroke, and death.
The authors claim this thoroughly described analysis is the
ﬁrst to assess the cost-effectiveness of tPA in a general European
context. Results are thus presented appropriately in euros.
However, it should be noted that the efﬁcacy data is based on
results from the National Institute of Neurological Disorders and
Stroke (NINDS) clinical study, and much of the resource use and
costs data were based on information obtained from a province
in Spain. As a result, readers should be cautioned to assess
whether these data are generalizable to the rest of Europe. The
model has several strengths, however. First, the model structure
was developed such that it can be easily applied to other coun-
tries. In addition, the authors performed a complete probabilistic
sensitivity analysis where they were careful in presenting the
varied input parameters, their baseline values and ranges, and
assumed probability distributions. From the detail that the
authors present, the result of this analysis could easily be
reproduced.
Ehlers et al. 2007
Ehlers et al. [14] developed a cost-utility model of timely admin-
istration of tPA with 24-hour neurology coverage and magnetic
resonance imaging (MRI) as compared with conservative treat-
ment over a time horizon of 1, 2, 3, and 30 years. An approach
similar to that used by Fagan et al. [6] was used where short-term
costs and outcomes were modeled using a decision-tree model,
and long-term consequences were modeled using a Markov
approach for a cohort of 50, 100, or 150 patients. The model
was programmed using TreeAge Pro software. In the acute
setting, patients treated for ischemic stroke had a risk of ex-
periencing a symptomatic ICH post treatment. After initial hos-
pitalization, surviving patients were discharged either to nursing
home, rehabilitation facility, or to their home with a health state
deﬁned by mRS. Following discharge, these patients experienced
an annual risk of recurrent stroke and increased mortality risk
over the general population. Risk of mortality and recurrent
stroke was assumed to be equal among all stroke patients regard-
less of mRS after discharge.
This well performed analysis is important as it speciﬁcally
considers the use of 24 hour neurology coverage and use of MRI
in conjunction with tPA. The model structure is based on previ-
ously published models in the literature. As a result, it has been
used for other analyses in other countries. The study, however,
presents an analysis from a Danish perspective (i.e., using Danish
resource use) with costs reported in US dollars. Limited details
are also provided around some of the input parameters used
within the model. Speciﬁcally, the authors do not present costs
data assumed after discharge from hospital or the transition
probabilities assumed between the mRS health states after the
initial event. It is also not clear what the distributions are
assumed for each input parameter varied in the probabilistic
sensitivity analysis (multiway sensitivity analysis, as it is referred
to in the paper).
Sinclair et al. 2001
Sinclair et al. [15] developed a decision-analytic model of acute
ischemic stroke treatment in Canada that examines impact on
costs and QALYs. Speciﬁcally, the model was designed to
compare tPA within 3 hours of stroke onset versus usual care (no
tPA) in a cohort analysis of 1000 patients. The model time
horizon was 30 years, after which 90% of the cohort was esti-
mated to have died. The model was designed using TreeAge
software. The model considers acute hospitalization and long-
term disability following discharge. The acute hospitalization
phase is a decision tree model that considers risk of symptomatic
ICH. At discharge, patients were classiﬁed by their functional
outcomes as deﬁned by mRS. Discharge location (home, reha-
bilitation hospital, or long-term care facility) was determined
based on mRS at 90 days following stroke event. The long-term
phase used a Markov approach with annual cycles to estimate
mortality and disability.
In this carefully performed analysis, the authors present a
model similar in design to that of a previously published model
[6]. This illustrates the capability of the model to be adapted to
other countries. The authors do note that the generalizability of
results may be limited by difﬁculty in adhering to the 3-hour time
window for administration of tPA. The authors thoroughly
describe the cost and probability estimates in the model.
However, presentation of sensitivity analyses is limited. Speciﬁ-
cally, only the results of one-way sensitivity analysis when con-
sidering changes in various costs and utilities are presented. The
impact of changes in other parameters is not presented. In addi-
tion, sensitivity analyses are presented to show the impact on the
average cost per QALY rather than the incremental cost per
QALY. Results of multivariate sensitivity analysis are not shown.
Thus, it is assumed that these analyses are not probabilistic. The
authors also note that limited availability of long-term cost data
present a challenge to modeling efforts.
Earnshaw et al. 2006
Earnshaw et al. [16] developed a cost-effectiveness and cost-
utility model of treatment for ICH. The model compared treat-
ment with rFVIIa at doses of 40, 80, and 160 mcg/kg to standard
care over the expected lifetime of the patient. The model was
developed for a cohort analysis using Microsoft Excel. A decision
tree approach was used to estimate 90-day (short-term) costs and
outcomes based on treatment arm. A steady-state approach was
assumed to follow patients over the remainder of their lifetime to
estimate long-term results. The long-term module estimated costs
and outcomes (mortality and QALYs) based on functional status
as deﬁned by mRS at 90 days following the acute stroke event.
This analysis is unique in that it was the ﬁrst and only one to
examine the costs and outcomes associated with a potential
pharmacologic treatment for ICH. The model structure and
input data are based on well-accepted stroke studies within the
published literature. Adaptation of this model to other countries
could be easily performed given availability of cost and survival
data by mRS score. A key limitation of this analysis is the
availability of long-term costs data, which are a key driver of the
results. In addition, failure of rFVIIa to meet its primary endpoint
within Phase-III clinical trials may be cause for concern.
Regardless, results of the analysis show how a pharmacologi-
cal treatment with potential to improve functional outcome and
patient survival may impact costs and outcomes.
Mihalopoulos et al. 2005
Mihalopoulos et al. [11] developed a spreadsheet model to
examine the burden and cost of stroke in Australia. The
MORUCOS model is programmed in a series of Microsoft Excel
worksheets while interacting with the decision-analysis software
packages of TreeAge and Palisade’s @Risk, and examines a
cohort of 30,895 ﬁrst-ever stroke patients. Two versions of the
model are presented and compared as part of a model validation.
The model considers ﬁrst-ever and recurrent stroke and is
comprised of three modules: the natural history module, which
followed the incidence of stroke and general mortality; the cost
module, which employed a microcosting approach and which
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considered the costs of stroke-related resource use, unit costs,
and productivity loss; and the outcomes module, which consid-
ered the comparative efﬁcacy of the treatments. The model time
horizon was the lifetime of the patient following stroke event.
A strength of this paper is that it presents a thorough valida-
tion of the developed model. In additions, the study clearly
presents sources for input parameter values. However, it is difﬁ-
cult to follow the detail around the model construct (i.e., how the
calculations behind the model work) and the actual input param-
eters values used to derive the model results. Based on the limited
information within the paper, it seems that it would be difﬁcult to
adapt this model for use in other countries, as it is highly data
driven. Authors also provide limited information as to how sen-
sitivity analysis is performed within the model, making replica-
tion of results difﬁcult.
Samsa et al. 1999
Samsa et al. [8] created an add-on analysis to the SPPM cost-
effectiveness model developed for stroke prevention [9], for
application to new treatments of acute ischemic stroke. The
model in this study estimates the lifetime cost-utility for a new,
hypothetical acute stroke treatment by using costs and outcomes
estimated from the SPPM, a semi-Markov simulation model and
applying to survival, QALYs, and cost data estimated within this
study. This add-on to the SPPM is designed as a cohort analysis.
Authors do not detail what software this model is programmed
in. However, given the outputs of the SPPM model, this model
could be easily programmed in any spreadsheet package. The
model estimates costs, expected life years, and QALYs as a func-
tion of steady state functional outcome (i.e., mRS) 6 months after
experiencing an acute stroke event. Patients are followed for risk
of stroke events (transient ischemic attack, ischemic stroke, hem-
orrhagic stroke, myocardial infarction) with costs and utility
weights applied to each time period.
This thoroughly described model builds upon a previously
developed comprehensive stroke model, the SPPM. As a result, it
is comprehensive in design. An important feature of this study is
that the authors derived estimates of the long-term impact on
survival and costs by patient perceived disability. Although these
estimates were obtained from a Delphi panel of ﬁve members, it
was structured to be as much evidence-based as it could be, and
agreement among panelists was robust. This study offers the
readers a very nice insight to the characteristics that an acute
stroke treatment would need to have in order to be cost-effective.
Perhaps a limitation of this analysis is its applicability to other
countries, as the data estimates were obtained from a US setting.
However, the methods outlined in the study could be applied to
obtain data for use in other countries.
Caro et al. 1999
Caro et al. [17] designed a decision-analytic model, called the
stroke treatment economic model (STEM), for estimating costs
of acute ischemic stroke treatment. This study presented the use
of this model through an example comparison of treatment with
lubeluzole to standard care. The model is composed of a short-
term (12-week) module and a lifetime long-term module. The
authors do not discuss in what software the model was pro-
grammed. The short-term module considered the initial hospital-
ization, posthospital care (outpatient services, rehabilitation,
retirement home, etc.), and medical equipment required as a
result of stroke. The long-term module used a Markov approach
to estimate the transition between ﬁve locations (rehabilitation
center, hospital, home, nursing home, and retirement home) and
death. The Markov module used annual cycles for the remainder
of the patient’s lifetime. The short-term and long-term modules
are connected via a bridge grouping survivors based on func-
tional status (based on BI score) and discharge location.
This study is unique in that it focuses on discharge location
rather than functional status at discharge. The authors describe a
detailed list of cost parameters considered by the model. In fact,
a strength of the model is that it takes a comprehensive look at
the cost to manage a stroke patient. Speciﬁcally, the short-term
module is built upon resource data obtained from the clinical
trial setting. Because of the source of this data, however, the
authors caution the user to consider the applicability of these
costs carefully when adapting the model for use in other coun-
tries. In addition, the model provides limited detail around the
actual input data used to run the presented analysis. As a result,
replication of the model results is difﬁcult. Authors do point out
the limitation that the availability of data to populate the model
in the long term. They recognize the limited data surrounding the
transitioning of patients following the stroke event and data
availability regarding the link between disability status and long-
term location. Presentation of the sensitivity around these limited
parameters would have strengthened the model.
Stahl et al. 2003
Stahl et al. [18] developed a cost-utility model of acute stroke
treatment. The model compared standard practice of delivering
tPA with more timely recognition of stroke and delivery of tPA as
recommended by the NINDS over the lifetime of the patient. This
model was developed as a discrete event simulation model using
SIMAN and Arena software. Short-term outcome measures
including survival and improvement in functional outcome (mea-
sured by mRS) were estimated at 10, 90, and 180 days, and at 1
year. Patients were followed annually thereafter for the remain-
der of their lifetime while accounting for recurrent stroke events
and death. Transition rates after 1 year were assumed identical
for all patients, independent of functional outcome following the
initial stroke event.
In this carefully performed study, the model presents a nice
overview of the process with which to treat an acute stroke event
upon arrival in the emergency department. The authors do a
good job in presenting the parameters, their values, and plausible
ranges that are assumed within the model. As a result, the model
could easily be reproduced. However, to properly run the simu-
lation, more detail around the assumed distributions for each of
the parameters would have to be provided. This model structure
could easily be adapted to other countries, as the 3-hour time
window for treatment restriction is prevalent in tPA’s indications
across countries. A potential limitation of the model is its
dependability on timing data, as this data may not be available
within all countries. However, success of the administration of
tPA for acute ischemic stroke patients depends highly on this
3-hour-window restriction. As such, data could easily be col-
lected for different regional settings.
Discussion
From this review, we identiﬁed publications related to the
development of decision-analytic models to analyze the cost-
effectiveness of acute stroke treatments. These articles ranged
from analyses of treatments for acute ischemic stroke to treat-
ments for ICH to stroke treatment in general. The analyses were
performed in a broad set of countries such as Sweden, the United
States, the UK, Australia, Canada, and Denmark. A summary of
modeling issues are provided in further sections.
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Types of Modeling Approaches and Health States
Currently published modeling analyses on stroke do vary in
approach, design, and complexity. Six of the models describe
themselves as Markov or semi-Markov in nature [5–8,13,15] and
two describe themselves as simulation models [17,18]. One may
be classiﬁed as a simple decision tree analysis [16], and two
describe themselves as decision tree/Markov model hybrids, in
which the short-term event is modeled using a decision tree
framework and Markov modeling is used to examine long-
term consequences [12,14]. Two models describe themselves as
spreadsheet-based models [10,11]. Regardless of the modeling
approach used, results and conclusions do not deviate much from
simpler models to the more complex models.
Although divided into very different modeling methodologies,
what becomes clear in the modeling of acute stroke treatment is
the consideration of the outcomes of treatment in two parts:
treatment of and immediate recovery from the index stroke
event and long-term management postevent. This is evident
in the hybrid models and is even seen in models such as
Chambers et al. [5], Fagan et al. [6], Sinclair et al. [15], and Caro
et al. [17].
During the treatment of an acute stroke event, health state
deﬁnitions based on treatment pathways are important. Depend-
ing upon the focus of the analysis, the index event can be
modeled as “one acute event” health state describing the treat-
ment and hospitalization associated with the acute event
[5–8,14–17]. Alternatively, the acute event maybe detailed to
consider each aspect of diagnosis and treatment as outlined in
Stahl et al. [18] and Sandercock et al. [12].
Regardless of the type of stroke event being treated, the time
since the onset of stroke symptoms is an important determinant
of stroke treatment and is an essential factor in predicting func-
tional outcome. In ischemic stroke, treatment with tPA has been
shown to be less effective beyond 3 hours from the onset of
stroke symptoms and thus has a strict indication to be initiated
within 3 hours of onset of symptoms [19,20]. This time window
restriction could soon change based on recent release of the
European Cooperative Acute Stroke Study 3 (ECLASS3) results,
which shows beneﬁt of tPA treatment up to 4.5 hours after stroke
onset (Hacke et al., 2008) [21]. Clinical trials for potential ICH
treatments considered similar issues [22,23]. Several models con-
sider the timing of administration of stroke treatment in some
manner [5–8,10–18]. Sandercock et al. speciﬁcally examine the
sensitivity of timing of administration of treatment, estimating
results for a population receiving ischemic stroke treatment
within 3 hours and within 6 hours [12]. As a result, timing of
administration should be considered within the model in some
manner, as the published clinical trials have demonstrated that
time is critical in timely diagnosis and treatment [19,22].
Within the various model structures, long-term management
has typically been deﬁned based on a patient’s functional
outcome postevent, as seen as an endpoint within the clinical
trials [5,6,8,12–17]. There are a number of measures of func-
tional outcome, including BI, mRS, and functional independence
measure (FIM). Table 3 shows measures of each scale. The most
commonly used metrics for measuring stroke disability in pub-
lished economic models have been the mRS and BI. Fagan et al.
[6] consider functional outcome as estimated by mRS at days 7 to
10 and months 3, 6, 9, and 12. Several other models [5,14–16]
considered functional outcome as deﬁned by mRS at 90 days
poststroke in their analyses. Samsa et al. [8] deﬁned functional
outcomes using mRS at 180 days. The BI was used by Mar et al.
[13] and Caro et al. [17], who estimated disability at one year
post stroke using the BI.
Model Time Horizon
As noted in various economic evaluation guidelines [24–26] the
time horizon that is appropriate to apply within an economic
evaluation is dependent upon the time at which full beneﬁts of
the intervention being analyzed can be realized. With treatment
of acute stroke, treatment beneﬁts may be realized for the
remainder of a patient’s lifetime as a result of improvements in
functional outcome. Thus, a lifetime time horizon is appropriate
to examine the impact of acute stroke treatments on the costs and
outcomes.
However, managed-care health plans within the United States
are often concerned with the cost-effectiveness of a particular
technology over a shorter time horizon (i.e., 2–3 years) to reﬂect
the typical patient enrollment duration. In other words, because
the average patient will leave a health plan within a 2- to 3-year
time horizon, the cost-effectiveness of that technology should be
examined over this time frame. We would argue that health plans
are doing themselves a disservice by restricting the time horizon
to a period equal to a patient’s average enrollment period.
Although it may be true that a patient may leave the plan before
the average enrollment period is up, it is also true that patients
continue to enter health plans. Thus, health plans will beneﬁt if
a particular technology was administered while the patient was
under a different health plan.
All of the models reviewed consider the lifetime perspective
for estimating the impact of acute stroke treatment on costs and
outcomes. Some models have presented results for both short-
term and lifetime perspectives [5,12,14]. This approach allows
the decision-maker to consider the short-term implications of a
new treatment while also viewing the long-term beneﬁt of the
treatment.
Postevent Health State Transitions
Amajor outcome of acute stroke clinical trials and a major driver
of both poststroke costs and outcomes is the functional status of
the patient following the index stroke event [6,8,14,16]. Patients
with greater disability may be assumed to have more severe
long-term health outcomes, require more medical resources, and
have a lower overall quality of life than those with minimal
impairment following stroke. Thus, following the index stroke
event, health states deﬁned based on functional outcome are
important to consider when developing a cost-effectiveness
model of stroke.
Table 3 Stroke functional outcome scales
Functional
outcome scale Measure
Modiﬁed Rankin
Scale [51]
0 = no symptoms at all
1 = no signiﬁcant disability
2 = slight disability
3 =moderate disability
4 =moderate severe disability
5 = severe disability
6 = death
Barthel Index [52] Ten-measure composite score of independence in the
following areas: feeding, bathing, grooming, dressing,
bowels, bladder, toilet use, transfers, mobility, and
stairs.A total score of 0 = complete disability, and a
score of 100 = complete independence.
Functional
Independence
Measure [53]
18-measure ordinal scale
1 = requiring total assistance
7 = completely independent
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In designing a cost-effectiveness model for acute stroke treat-
ment, changes between health states over time based on func-
tional outcome should be considered. Two of the models
reviewed assume a steady-state disability for estimating long-
term outcomes [8,16]. Others enable patients to transition
between functional outcome-based health states poststroke.
Fagan et al. [6] and Ehlers et al. [14] state that they allow
patients to transition between the six mRS categories post the
index event.
One hurdle to overcome is that long-term data detailing the
natural history for survivors of acute stroke events are limited in
the published literature. Most clinical studies generally report
functional outcome up to 90 days [19,22] and only one study
reported these outcomes up to 1 year following stroke [20]. Data
are limited beyond that time point. In the absence of these data,
it has been assumed that a steady state level of functional status
can be reached. In particular, Samsa et al. [8] convened a panel of
experts with backgrounds in neurology, rehabilitation, physical
therapy, and epidemiology who came to a consensus that a steady
state mRS would tend to occur within 3–6 months from the
index stroke event. However, they recognized that further recov-
ery is possible and that function may continue to improve for
12 or more months after the stroke. They speciﬁcally noted that
patients with initial mRS  2 would usually require less time to
reach steady state, most likely within 3 months. Patients with
mRS  3 would require more time to reach steady state. Samsa
et al. [8] conﬁrmed this assumption through a review of the
published literature.
Poststroke Mortality
Mortality within these models tends to be reported as short-term
mortality as a result of the acute stroke event and long-term
mortality. Short-term mortality is typically estimated from short-
term clinical trial studies of stroke treatment, as this is a direct
outcome considered in stroke care. Long-term mortality risk is
more difﬁcult to estimate accurately. In addition to the baseline
mortality risk for the general population, there is an increased
risk of mortality as a result of having had a stroke previously.
There may also be an additional mortality risk associated with
the disability resulting from a stroke event. This risk may be
directly correlated with either the severity of disability or to
discharge status. Samsa et al. [8] presented a set of mortality
multipliers based on poststroke mRS status. Earnshaw et al. [16]
followed the approach recommended by Samsa et al. (1999) [8],
whereas Caro et al. [17] estimated long-term, poststroke mortal-
ity risk as a function of patient discharge location. The authors
suggested that discharge location may serve as a better proxy for
functional outcome.
Several articles do not differentiate mortality by functional
status poststroke event. Speciﬁcally, Stahl et al. [18] assumed the
same long-term, annual mortality rate for all survivors of stroke,
regardless of the severity of the stroke. Sandercock et al. [12]
estimated mortality risk based on age and presence (or absence)
of a recurrent stroke. Caro et al. [17] noted that data on pro-
gression among functional outcome categories years after the
stroke are limited, and thus estimates of disease transition are
purely speculative. In the absence of such data, it may not be
appropriate to assume a difference in mortality based on
functional outcome. Assuming that poststroke mortality is not
dependent upon functional outcome would be a conservative
assumption; it would stand to reason that if a difference in
mortality across levels of functional status did exist, it would
only further differentiate the more effective treatment from its
comparator.
Health State Utilities
The measurement of health state utilities is a common approach
for estimating the beneﬁt of a treatment for stroke. These utilities
determine the quality of life for survivors of stroke and allow
for differentiation between severe disability and normal health.
Several studies have been performed that access patient utility
preference given functional outcome, which is a key outcome in
most acute stroke treatment clinical trials [27–35]. As such, it is
natural for utilities to be based on the health state measures (i.e.,
mRS, BI, etc.) used in the clinical trials.
All but three of the models [10,11,17] considered utilities to
derive quality-adjusted life years. The utilities that are incorpo-
rated into the models are based on functional outcome. Because
mRS has frequently been used in the published models to repre-
sent functional outcome, several articles map the utilities into
these functional groups. Speciﬁcally, Stahl et al. [18] estimate
seven utility values corresponding to each mRS value based on
utility preference studies [27,29,32–34,36–38] and other model
studies [6,8,35,38] map utilities from Solomon et al. [29] and
Gage et al. [27] to mRS. Fagan et al. [6] map utilities from
Solomon et al. [29] and Mark et al. [36] to mRS, where an mRS
score of 5 results in a negative utility value, indicating that this
health state is worse than death. This analysis was the only model
reviewed that assumed a negative utility value for any disability
level. Mar et al. [13] used the BI to estimate the percentage of
patients who are dead (BI = 0), disabled (BI  95), and autono-
mous (BI > 95). These utilities were derived from EuroQoL
Group [39] and Badia et al. [40].
Considering utility by multiple severity categories rather than
simply distinguishing between disabled and nondisabled patients
allows the model to differentiate to a greater degree the quality of
life for the patient poststroke and may be a more appropriate for
estimating QALYs. Patients with mild-to-moderate disability
may be substantially better off than those with severe or complete
disability, as suggested by a few studies [6,18,27].
Cost Estimation
Given the natural treatment pathway of stroke management,
direct costs have been considered from a short-term and a long-
term perspective. Depending upon the perspective of the analysis,
indirect costs can also be a key driver of the ultimate outcome of
the analysis.
Short-Term Costs
Short-term costs include the direct costs of emergency room and
inpatient care for treatment of acute stroke, as well as the reha-
bilitation costs (i.e., outpatient rehabilitation, skilled nursing
facility, home health, etc.) following discharge from the hospital
up to the point at which the patient achieves maximum recovery
from stroke (steady state functional status). These costs are
assumed to cover the direct costs associated with the acute stroke
treatment and rehabilitation until a steady state disability status
is achieved.
Short-term costs may be estimated directly from clinical trial
data. Alternatively, initial hospital length of stay may be used
along with a per-diem hospital cost to estimate the initial hospi-
talization costs. Depending on the time horizon over which the
short-term costs are estimated, the patient may incur additional
outpatient costs, rehabilitation care costs, nursing home costs,
home health costs, or other costs associated with the post stroke
rehabilitation and care process.
Chambers et al. [5] consider acute care costs of stroke treat-
ment as well as the costs of treatment of any other acute vascular
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event within the ﬁrst 90 days. Earnshaw et al. [16] estimate the
costs of the initial hospitalization using clinical trial length-of-
stay data and cost estimates from an analysis of Medicare claims
data. They also include the short-term costs for rehabilitation
care for patients with mRS 2–3 and skilled nursing home care for
patients with mRS 4–5. Fagan et al. [6] estimated short-term
costs as 1 day of ICU, treatment and administration costs, phy-
sician costs, and any inpatient or outpatient rehabilitation costs.
Short-term costs should include the cost of inpatient stay.
These data may be estimated from length of stay data multiplied
by a unit cost per day or from average cost per stroke event
obtained from the published literature. A limitation of this
approach is that most stroke patients would use greater resources
in the beginning of the inpatient stay, thus the average cost for the
ﬁrst few days may be signiﬁcantly greater than toward the end,
which is often challenging to separate. Short-term costs may also
include postevent inpatient stay costs. These costs may allow for
differentiation between treatments, but current data for this dif-
ferentiation are limited. In addition, there may be substantial
variation in costs associated with rehabilitation and poststroke
care during the short-term phase, depending on the functional
outcome at discharge.
Long-Term Costs
Long-term costs are assumed to be costs incurred as a result of a
stroke that occurs after the patient has reached a steady-state
functional outcome. These costs may include subsequent hospi-
talizations, costs of recurrent stroke, and any long-term costs of
medical equipment required as a result of stroke, as well as
any service care required (rehabilitation, nursing home, home
health services, etc.) as a result of stroke disability.
It is a challenge to estimate long-term costs post index event
for inclusion in a cost-effectiveness model. It is important to
consider this phase of the model because much of the differen-
tiation in both costs and outcomes are observed in the long term,
as differences in functional outcome become more important
over time. However, estimating long-term costs may be compli-
cated. In order to estimate these costs, it is important to deter-
mine what is driving costs. Discharge status and functional
outcome at the end of the short-term phase are potential options
for estimating long-term costs. Those patients who are dis-
charged to their homes with minimal disability can be expected
to have greatly reduced costs. Conversely, patients with severe
disability that are discharged to skilled nursing/long-term insti-
tutional care facilities will have signiﬁcantly greater costs.
However, there may not be a direct link between functional
outcome and discharge status.
In the US estimating long-term costs has speciﬁcally shown to
be a challenge by Stahl et al. [18] and Caro et al. [17]. Stahl et al.
[18] estimated long-term costs based on functional outcome. The
patient’s mRS score determined whether the patient was dis-
charged to inpatient rehabilitation care and then a nursing home
(mRS  2), or to brief outpatient rehabilitation care facilities and
then to home (mRS < 2). Caro et al. [17] estimate long-term costs
primarily as a function of location (i.e., home, hospital, nursing
home, etc). Their rationale for this approach is that there is a lack
of data on the natural history for poststroke survivors. They felt
that long-term poststroke costs are most likely driven by dis-
charge location.
Nearly every study indicated the difﬁculty in assessing long-
term costs associated with care for acute stroke. Few publications
address these long-term poststroke costs. Leibson et al. [41] esti-
mate resource utilization 1 year poststroke for several levels of
stroke severity based on claims data. Taylor et al. [42] estimate
lifetime costs of stroke care using 2-year claims data. However,
these studies are very dated and do not address the issue of
potential variation in cost over time. Despite the limited avail-
ability of data, it is important to consider long-term costs in any
economic model of stroke as these costs will drive cost-
effectiveness results.
Other Indirect Costs
While stroke has a distinct direct cost for treatment and
postevent management, there are indirect costs that may be con-
sidered as well. Most of the cost-effectiveness analyses of acute
stroke treatment are performed from a payer perspective [6,10–
17]. Thus, few published analyses consider indirect costs
[5,7,13,18]. These studies state that they perform their analysis
from a societal perspective. Even though few analyses considered
indirect costs, these costs can be quite substantial as a result of
high-morbidity poststroke and associated caregiver burden. Indi-
rect costs may include community-based costs and social support
services. Additionally, indirect costs may include the cost of lost
employment productivity for a stroke patient. However, these
costs are likely to be low considering that stroke patients tend to
be an elderly population. Another indirect cost associated with
stroke is caregiver burden. While some stroke patients receive
institutional long-term care or professional home health service;
other patients may be cared for in some capacity by an informal
caregiver. For these patients, the emotional, physical, and mon-
etary burden associated with providing such care may be an
indirect cost to consider.
The challenge in estimating caregiver burden is the lack of
available literature regarding these estimates. Dewey et al. [43]
estimated the impact of caregiver burden, focusing on work time
lost. They estimated total costs for caregiver work loss based on
an Australian interview survey of caregivers for stroke patients
regarding time spent providing care. Taylor et al. [42] estimated
indirect costs based on the productivity loss incurred by the
stroke patient. But these analyses may not cover the entire costs.
Productivity loss in itself is a difﬁcult measure as absenteeism and
presenteeism in the workplace may be difﬁcult to accurately
estimate. Similarly, the emotional burden for caregivers may be
difﬁcult to quantify.
Obtaining estimates of stroke-related indirect costs associated
with caregiver burden and lost productivity and functionality for
the patient may be difﬁcult. These costs have been considered to
a limited extent in the analyses. While indirect costs are a rel-
evant consideration in determining the costs associated with
stroke treatment, including indirect costs in a model will only
serve to magnify the cost-effectiveness.
Examining Parameter Uncertainty
Most of the stroke models reviewed examine the impact of
uncertainty around key input parameters. One-way sensitivity
analysis is the most prevalent form of uncertainty analysis and is
conducted in the analyses of eleven of the thirteen articles
[6–8,10–12,14–18]. Another article references results of sensitiv-
ity analysis to be presented in a previous publication [5]. In these
articles, analyses are very comprehensive and examine the impact
on results of changing most, if not all, input parameters. For
example, Samsa et al. [8] performed a series of one-way and
two-way sensitivity analyses on variations of their hazard ratios,
costs, discount rates, and utilities.
Six of the articles present the results of both one-way and
probabilistic-type sensitivity analyses [6,7,11,12,14,16]. Most
often the results of probabilistic analyses are presented in the
form of 5th and 95th percentiles around the differences in each
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outcome as seen in Fagan et al. [6] and Sandercock et al. [12].
Earnshaw et al. [16] and Mar et al. [13] present results of proba-
bilistic sensitivity analysis in the form of a scatter plot and the
probability that the incremental cost per quality-adjusted life
year is cost-saving and cost-effective. Due to the uncertainty of
parameter estimates, it is recommended that both one-way and
probabilistic sensitivity analyses be presented in an economic
model.
Model Validation
An essential part of any economic evaluation is the validation of
the deﬁned model structure, assumptions, data inputs, calcula-
tions, and results. As a result, guidance around decision-analytic
modeling validation has been published [44–49]. As Mandelblatt
et al. had stated “models are only as good as their ability to
represent reality at the level needed to draw useful conclusions;
this in turn, depends on their structure and on the assumptions
that go into the model” [50].
Validation through expert review is important and creates
acceptance of the analytic approach.
It is also essential that any economic model produce results
that are consistent with what one would expect for treating that
condition in the real world. Results can be validated through
comparison to clinical or database studies. In the absence of real
data (as is the case for most models), one may need to consider
a comparison with other models published in the literature.
Error-checking procedures should also be conducted to conﬁrm
that logical calculations and that parameter values are applied
correctly.
Only one of the articles reported results from internal or
external validation [11]. The authors presented an internal vali-
dation that illustrated the differences in cost results for two
versions of the model and discussed the reasons for the differ-
ences in costs. A few of the other studies provided a descrip-
tion of the validation measures taken within their analysis
[5,8,10,12]. Speciﬁcally, Samsa et al. (1999) [8] mention the vali-
dation performed on a previously published version of the model.
They also note that the model underwent a comparison of
outputs with inputs (internal validation) and a comparison of
model-based results with that of other cohorts (external valida-
tion). Chambers et al. [5] state that their model was reviewed by
an advisory board of clinicians and health economists during
development. Considering the variety of modeling approaches
presented, some measure of between-model validation should be
considered to judge the overall credibility of the model.
Conclusions
Our review of the published economic models illustrates that
there is some variability in model structures, model complexity,
and long-term data assumptions among models developed to
examine the cost-effectiveness of acute stroke treatments.
However, ultimately the model structures are fairly similar. The
published analyses have shown that the cost-effectiveness of
acute stroke treatment is extremely sensitive to the impact that a
treatment has on mortality and functional outcome [8,16]. As
such, the lack of long-term natural history and cost data suitable
for incorporation into a decision model is a major limitation
in the current development of acute stroke treatment cost-
effectiveness models. To more accurately estimate long-term out-
comes, data on disease progression over time is necessary.
Furthermore, long-term cost estimates by functional outcome
and/or patient discharge location need to be performed to more
accurately assess the costs associated with these poststroke health
states. Research should be undertaken to estimate inpatient and
rehabilitation costs by disability level or discharge location to
provide short-term cost estimates suitable for economic models.
Progress in estimating these inputs would greatly facilitate the
development of a sound cost-effectiveness model.
Based on the review, we recommend that the complexity of
models for examining the cost-effectiveness of an acute stroke
treatment be kept to a minimum such that it can incorporate
the currently available data without making a large number of
assumptions around the data. The model should be constructed
to address two phases of treatment: 1) treatment of the index
acute stroke event, and 2) long-term management and prevention
of stroke where the ﬁrst phase is built around data obtained from
the clinical trials as much as possible and the second phase is
built upon natural history data. Key drivers of costs and out-
comes are beneﬁts gained by avoiding mortality and severe dis-
ability. As a result, assumptions and values around these data
should be considered carefully. As seen in the majority of the
analyses, it is recommended that results be reported as lifetime
incremental cost per quality-adjusted life years for the remainder
of the patient’s lifetime in order to capture the full value and
beneﬁts of treatment. As strokes also affect caregivers, indirect
costs are important to consider. However, such costs are difﬁcult
to assess. Both one-way and probabilistic sensitivity analyses
should be performed in order to provide decision-makers with a
complete examination of the sensitivity of the baseline results to
changes in input parameters and model assumptions.
With limited health-care resources, it is important to allocate
resources to interventions that are most cost-effective (i.e., have
the greatest beneﬁt per cost). In the absence of direct head-
to-head comparison data, modeling techniques are widely used
to calculate cost-effectiveness. These exercises enable decision-
makers to examine the effects of a new therapy and its potential
impact on costs and quality of life in a cost-efﬁcient manner. As
such, it is very important that the decision-analytic modeling of
treatment of acute ischemic stroke, ICH, or any stroke be such
that it most closely represents the actual treatment pathways,
resource use, and outcomes associated with the treatment and
management of these conditions, in order to provide a valid tool
for making important decisions regarding novel treatments.
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